In the KEYNOTE 355 trial comparing treatment of the physician’s choice (several chemotherapeutic agents allowed) in combination with either placebo or pembrolizumab for the first-line treatment of advanced TNBC, PD-L1 status was assessed by the combined positive score (CPS), which takes into account not only PD-L1 expression on immune cells but also on tumor cells. Here, CD274 is linked to neoplasm.